Consensus Cloud Solutions (CCSI) is one of the more quietly compelling cases on the current Magic Formula screen: a healthcare-focused cloud software business with 80% gross margins and roughly 54% adjusted EBITDA margins, trading at about 7.5x trailing earnings and under 6x forward earnings while the broader S&P 500 sits at roughly 32x. MagicDiligence gives CCSI a Pass rating, and the stock has also shown strong positive relative strength versus the market over the past six months. The market's skepticism is real, but the numbers keep describing a business that generates far more cash than the stock price implies.

What the Market Sees

The bear framing on CCSI writes itself. The company's best-known brand is eFax — a product launched in 1996 that has become cultural shorthand for legacy technology. Revenue has been essentially flat for two years: $362.6 million in 2023, $350.4 million in 2024, and $349.7 million in 2025. The company carries $562 million of debt, pays no common dividend, and operates in a segment the 10-K itself identifies as dependent on an industry still using fax as its dominant clinical communication protocol.

The stock spent most of the second half of 2025 trading in the low twenties — below $22 — before rallying sharply in early 2026 on the strength of a clean Q4 beat and improving Q1 guidance. Even after a strong run, CCSI has only recovered to a valuation that still looks modest against any reasonable measure of its earnings power.

What Consensus Actually Is

The flat revenue headline obscures what has actually been happening inside the business. Consensus spun out of Ziff Davis in October 2021 as a cloud-fax company with a large tail of small-business subscribers. What it has been doing since is a slow but deliberate shift: letting the consumer and small-office fax base contract while investing in enterprise healthcare and government customers who need secure, HIPAA-compliant, interoperable data exchange.

The Corporate channel — which covers large enterprises, healthcare systems, and government agencies — grew from $170 million in 2021 to $222.7 million in 2025, a 7% compound annual growth rate. In Q1 2026 it accelerated further, rising 8.2% year-over-year to $58.7 million, which management described as the strongest corporate growth quarter since Q4 2022. The small-office SoHo channel has been shrinking deliberately: $162.9 million in 2023, $141.3 million in 2024, $127 million in 2025. Total revenue looks flat because one line is growing while the other is being strategically run down.

The product suite has expanded well beyond fax. eFax Conductor provides healthcare interface engine and interoperability infrastructure. eFax Clarity uses NLP and AI to convert unstructured clinical documents — faxes, scans, referrals — into structured, actionable data for EHR systems. eFax Unite is a single platform for hospitals to manage cloud fax, direct messaging, and patient information queries in a unified workflow. Consensus is also the only digital cloud fax provider certified under both HITRUST and FedRAMP High Impact, clearances that give it near-exclusive access to certain federal and regulated healthcare contracts.

With 703,000 customer accounts across 46 countries, a software delivery model, and a small 520-person workforce, the business generates roughly $672,000 of revenue per employee. That is the profile of a company that has already done the hard infrastructure work.

What the Numbers Say

The 2025 full-year results were cleaner than the flat revenue line suggests. Net income was $84.5 million on $349.7 million of revenue, producing a 25% net margin. Adjusted EBITDA was approximately $186 million at a 53% margin. Net cash provided by operating activities grew to $136.1 million from $121.7 million in 2024, and after $30.2 million of capital expenditures, free cash flow came to approximately $106 million — a cash yield of roughly 17% on the current market capitalization.

Q1 2026 continued that momentum. Revenue rose 1.5% to $88.5 million, beating consensus by $1.1 million. Adjusted EPS of $1.52 beat estimates by $0.13, a 10.9% increase year-over-year. Free cash flow surged to $38.5 million from $33.7 million, and management reaffirmed full-year 2026 guidance of $350 million to $364 million in revenue, $182 million to $193 million of adjusted EBITDA, and $5.55 to $5.95 of adjusted diluted EPS.

Here is where the valuation gap becomes stark. At $34.14 per share and approximately 18.4 million shares outstanding, CCSI's market capitalization is roughly $628 million. The forward P/E on the 2026 adjusted EPS guidance midpoint of $5.75 is about 5.9x. The trailing GAAP P/E is 7.45x. Compare that with the S&P 500, which trades at roughly 32x trailing earnings per Multpl's current reading of S&P 500 reported earnings. CCSI's application software peers trade at a sector average closer to 81x. Even on enterprise value — approximately $1.1 billion including debt net of cash — the stock trades at about 5.9x forward adjusted EBITDA against a guidance midpoint of $187.5 million. That is pricing typically reserved for businesses in severe structural distress, not one generating 17% free cash flow yields.

Those multiples look even more striking in context of CCSI's own history. In its first year as a public company in late 2021 and early 2022, the stock traded above $60 with earnings per share much lower than what the company produces today. The business has grown its earnings per diluted share from $3.94 in 2023 to $4.35 in 2025, a 10% increase, while the share count has shrunk through buybacks. Management has repurchased $72.1 million in stock since the program launched, including $17 million in Q1 2026 alone, with $27.9 million of authorization remaining.

What Could Still Go Wrong

The bull case is not risk-free. Corporate monthly churn has climbed to 3.03% in early 2026, up from 1.49% in 2023, and that trend needs to be watched carefully as enterprise contracts renew in a more competitive environment. Total debt of $562 million is real, with $348 million of 6.5% senior notes maturing in October 2028 and the remaining $214 million of credit facility borrowings due the same year. The 2028 maturity wall requires either a refinancing or a material paydown from cash generation — achievable given current run rates, but not without execution risk.

The biggest strategic question is whether Consensus can actually convert its interoperability platform into recurring revenue before fax usage contracts further. The company itself acknowledges in its 10-K that its healthcare interoperability products "currently represent an immaterial portion of revenues." eFax Clarity, eFax Conductor, and eFax Harmony are positioned well, but positioned is not the same as scaled. A post-Q4 2025 Seeking Alpha analysis framing CCSI as a potential "re-rating from fax utility to intelligence layer" captures the optionality but also the distance that still needs to be traveled. The Globe and Mail noted in May 2026 that Consensus is attempting to "balance growth with leverage" — an accurate summary of the tension between investing in the next chapter and servicing a debt stack that leaves limited room for error.

Subsequent to year-end 2025, management disclosed that Irish tax authorities have opened a review covering tax years 2023 and 2024. The company believes it has appropriately reserved for its tax positions, but the review adds a modest layer of uncertainty.

What The Case Rests On

CCSI does not need its interoperability products to become a high-growth revenue engine to justify a higher price. It only needs the corporate channel to hold its momentum, the 54% EBITDA margins to stay intact, and the share count to keep declining as the buyback program absorbs stock at current prices. On that base case, the business is generating earnings and cash flow at a rate that looks materially undervalued against both the broad market and any comparable software company with similar margin profiles and recurring revenue characteristics.

Current CCSI read Value
MagicDiligence verdict Pass
Momentum read Positive 6M vs SPY
Why it screens High recurring-revenue margins, strong free cash flow, and a compressed valuation
Main bull point 80% gross margins and ~17% free cash flow yield, priced at 6x forward earnings while the market trades at 32x
Main risk Corporate churn, 2028 debt wall, and healthcare interop products not yet contributing material revenue

Consensus Cloud Solutions does not need a narrative upgrade to work from here. It needs the enterprise channel to keep growing, the margins to stay wide, and the market to stop treating a mature, high-margin SaaS business like a dying fax company.

If you want to compare CCSI with the rest of the current shortlist, go back to the current MagicDiligence screen results.

References